Operating Lease, Payments of Enliven Therapeutics, Inc. from 31 May 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Enliven Therapeutics, Inc. quarterly and annual Operating Lease, Payments in USD history and change rate from 31 May 2019 to 31 Dec 2025.
  • Enliven Therapeutics, Inc. Operating Lease, Payments for the quarter ending 31 Dec 2025 was $117,000, a 166% increase year-over-year.
  • Enliven Therapeutics, Inc. Operating Lease, Payments for the twelve months ending 31 Dec 2025 was $400,000, a 33% increase year-over-year.
  • Enliven Therapeutics, Inc. annual Operating Lease, Payments for 2025 was $400,000, a 33% increase from 2024.
  • Enliven Therapeutics, Inc. annual Operating Lease, Payments for 2024 was $300,000.
Source SEC data
View on sec.gov
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Change (%)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Change (%)

Enliven Therapeutics, Inc. Quarterly Operating Lease, Payments (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $400,000 $117,000 +$73,000 +166% 01 Oct 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
Q3 2025 $327,000 $100,000 +$14,000 +16% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $313,000 $100,000 +$15,000 +18% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $298,000 $83,000 -$2,000 -2.4% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $300,000 $44,000 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
Q3 2024 $86,000 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $85,000 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $85,000 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q1 2022 $69,000 +$1,000 +1.5% 01 Jan 2022 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q1 2021 $68,000 01 Jan 2021 31 Mar 2021 10-Q 11 May 2021 2021 Q1
Q2 2019 $300,000 01 May 2019 31 May 2019 10-Q 11 May 2021 2021 Q1

Enliven Therapeutics, Inc. Annual Operating Lease, Payments (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $400,000 +$100,000 +33% 01 Jan 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
2024 $300,000 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
2021 $249,000 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.